Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study

[1]  D. Anaby,et al.  Neurite density of white matter significantly correlates with tuberous sclerosis complex disease severity , 2022, NeuroImage: Clinical.

[2]  L. Lagae,et al.  Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex , 2022, Neurology.

[3]  D. Rotaru,et al.  Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis , 2021, JCI insight.

[4]  H. Weiner,et al.  Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. , 2021, Pediatric neurology.

[5]  Hong Shi,et al.  Everolimus inhibits PI3K/Akt/mTOR and NF-kB/IL-6 signaling and protects seizure-induced brain injury in rats , 2021, Journal of Chemical Neuroanatomy.

[6]  P. Zanotti-Fregonara,et al.  Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[7]  Meryem Temiz-Reşitoğlu,et al.  mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats. , 2021, Canadian Journal of Physiology and Pharmacology.

[8]  D. Kaping,et al.  mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus , 2021, Journal of neurodevelopmental disorders.

[9]  J. Hatazawa,et al.  Clinical evaluation of neuroinflammation in child-onset focal epilepsy: a translocator protein PET study , 2021, Journal of neuroinflammation.

[10]  H. Chugani,et al.  TLR7 activation in epilepsy of tuberous sclerosis complex , 2019, Inflammation Research.

[11]  Sergiu Groppa,et al.  Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging , 2019, NeuroImage: Clinical.

[12]  M. Mizuguchi,et al.  Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan , 2019, Brain and Development.

[13]  M. Jaatun,et al.  Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study , 2018, Epilepsia open.

[14]  Akira Yoshii,et al.  Multiple Critical Periods for Rapamycin Treatment to Correct Structural Defects in Tsc-1-Suppressed Brain , 2018, Front. Mol. Neurosci..

[15]  J. French,et al.  Everolimus for treatment-refractory seizures in TSC , 2018, Neurology. Clinical practice.

[16]  H. Kawai,et al.  Longitudinal Findings of MRI and PET in West Syndrome with Subtle Focal Cortical Dysplasia , 2018, American Journal of Neuroradiology.

[17]  N. Stence,et al.  Significance of FDG-PET Hypermetabolism in Children with Intractable Focal Epilepsy , 2018, Pediatric Neurosurgery.

[18]  M. Endzinienė,et al.  Different MRI-defined tuber types in tuberous sclerosis complex: Quantitative evaluation and association with disease manifestations , 2017, Brain and Development.

[19]  Q. Pittman,et al.  Neurobehavioral comorbidities of epilepsy: Role of inflammation , 2017, Epilepsia.

[20]  Orrin Devinsky,et al.  The genomic landscape of tuberous sclerosis complex , 2017, Nature Communications.

[21]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[22]  N. Mori,et al.  Depiction of microglial activation in aging and dementia: Positron emission tomography with [11C]DPA713 versus [11C](R)PK11195 , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Wang-Tso Lee,et al.  Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures , 2017, Journal of Neuroinflammation.

[24]  S. T. Govindarajan,et al.  Neuroinflammatory component of gray matter pathology in multiple sclerosis , 2016, Annals of neurology.

[25]  R. Kuzniecky,et al.  Transient and chronic seizure‐induced inflammation in human focal epilepsy , 2016, Epilepsia.

[26]  Pavel Krsek,et al.  Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex , 2016, PloS one.

[27]  W. Guo,et al.  Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex , 2016, Journal of Neuroinflammation.

[28]  H. Huppertz,et al.  Morphometric MRI analysis enhances visualization of cortical tubers in tuberous sclerosis , 2015, Epilepsy Research.

[29]  P. Deyn,et al.  Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis , 2015, Neurobiology of Disease.

[30]  N. Rensing,et al.  Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex , 2015, Neurobiology of Disease.

[31]  Kimberly J. Jenko,et al.  Neuroinflammation in Temporal Lobe Epilepsy Measured Using Positron Emission Tomographic Imaging of Translocator Protein. , 2015, JAMA neurology.

[32]  Jeih-San Liow,et al.  Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein , 2015, The Journal of Nuclear Medicine.

[33]  R. Boellaard,et al.  Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  Ukpong B. Eyo,et al.  Neuronal Hyperactivity Recruits Microglial Processes via Neuronal NMDA Receptors and Microglial P2Y12 Receptors after Status Epilepticus , 2014, The Journal of Neuroscience.

[35]  J. Simpkins,et al.  mTOR Signaling Inhibition Modulates Macrophage/Microglia-Mediated Neuroinflammation and Secondary Injury via Regulatory T Cells after Focal Ischemia , 2014, The Journal of Immunology.

[36]  K. Mizuno,et al.  Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study , 2014, The Journal of Nuclear Medicine.

[37]  Nils Z. Borgesius,et al.  TORC1‐dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice , 2013, Annals of neurology.

[38]  Hui Yang,et al.  Expression of the interleukin 17 in cortical tubers of the tuberous sclerosis complex , 2013, Journal of Neuroimmunology.

[39]  E. Aronica,et al.  Epilepsy and brain inflammation , 2013, Experimental Neurology.

[40]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[41]  Federico E. Turkheimer,et al.  Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo , 2012, NeuroImage.

[42]  J. Hirvonen,et al.  Increased In Vivo Expression of an Inflammatory Marker in Temporal Lobe Epilepsy , 2012, The Journal of Nuclear Medicine.

[43]  Q. Pittman,et al.  Cytokines and brain excitability , 2012, Frontiers in Neuroendocrinology.

[44]  M. Mizuguchi,et al.  Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex , 2012, Nature Communications.

[45]  D. Franz.  Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis , 2011, Expert review of anticancer therapy.

[46]  K. Kotulska,et al.  Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex , 2011, Epilepsia.

[47]  Robert B. Innis,et al.  Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands , 2011, The Journal of Nuclear Medicine.

[48]  Elizabeth A. Thiele,et al.  MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex , 2010, Journal of Neurology.

[49]  S. Camposano,et al.  The natural history of epilepsy in tuberous sclerosis complex , 2009, Epilepsia.

[50]  J. Rosenow,et al.  Cellular injury and neuroinflammation in children with chronic intractable epilepsy , 2009, Journal of Neuroinflammation.

[51]  J. Peltola,et al.  Levels of IL-1β and IL-1ra in Cerebrospinal Fluid of Human Patients after Single and Prolonged Seizures , 2009, Neuroimmunomodulation.

[52]  Sunhee C. Lee,et al.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain , 2009, Neuropathology and applied neurobiology.

[53]  G. Mathern,et al.  Increased activation of Iba1+ microglia in pediatric epilepsy patients with Rasmussen's encephalitis compared with cortical dysplasia and tuberous sclerosis complex , 2009, Neurobiology of Disease.

[54]  Mirela V. Simon,et al.  Are cortical tubers epileptogenic? Evidence from electrocorticography , 2009, Epilepsia.

[55]  K. Stuhlmeier,et al.  The TSC-mTOR signaling pathway regulates the innate inflammatory response. , 2008, Immunity.

[56]  Alcino J. Silva,et al.  Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis , 2008, Nature Medicine.

[57]  M. Eliasziw,et al.  Assessing severity of epilepsy in children: Preliminary evidence of validity and reliability of a single-item scale , 2008, Epilepsy & Behavior.

[58]  H. Baskin.  The pathogenesis and imaging of the tuberous sclerosis complex , 2008, Pediatric Radiology.

[59]  P. Crino,et al.  The tuberous sclerosis complex. , 2006, The New England journal of medicine.

[60]  G. Mathern,et al.  FDG‐PET/MRI Coregistration and Diffusion‐Tensor Imaging Distinguish Epileptogenic Tubers and Cortex in Patients with Tuberous Sclerosis Complex: A Preliminary Report , 2006, Epilepsia.

[61]  E. Aronica,et al.  Evidence of activated microglia in focal cortical dysplasia , 2006, Journal of Neuroimmunology.

[62]  H. Huhtala,et al.  Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration , 2004, Journal of Neuroimmunology.

[63]  P. Bolton,et al.  The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex , 2004, Archives of Disease in Childhood.

[64]  C. Ferrie.  Intractable Focal Epilepsy , 2001 .

[65]  H. Northrup,et al.  Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria , 1998, Journal of child neurology.

[66]  W. B. Woodhurst,et al.  Reactive microglia in hippocampal sclerosis associated with human temporal lobe epilepsy , 1995, Neuroscience Letters.

[67]  Lack of Correlation between Tuber Number and Cognitive Level in Mild TSC Patients: a Clinical and Genetic Study , 2020 .

[68]  Michael R. Johnson,et al.  Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls , 2017, Seizure.

[69]  S. Segal,et al.  Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[70]  E. Roach,et al.  Tuberous sclerosis complex. , 2015, Handbook of clinical neurology.

[71]  B. King,et al.  Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. , 2015, Pediatric neurology.

[72]  W. Grajkowska,et al.  Brain lesions in tuberous sclerosis complex. Review. , 2010, Folia neuropathologica.

[73]  D. Kwiatkowski,et al.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. , 2001, American journal of human genetics.

[74]  P. Weissberg,et al.  Inflammatory mechanisms. , 2001, British medical bulletin.